Table 1 Characteristics of study sample

 Age, months, median (IQR)

78 (33.50–163.00)

31.50 (26.24–40.00)

 Male, % (n)

52.7% (29)

42.7% (47)

 Day of illness at the time inclusion^a, median (IQR)

3 (2–3)

3 (3–4)

 pSOFA score, % (n)

2 = 38.2% (21)

3 = 27.3% (15)

4 = 14.5% (8)

5 = 10.9% (6)

6 = 1.8% (1)

7 = 1.8% (1)

9 = 3.6% (2)

10 = 1.8% (1)

0 = 86

1 = 24

 ICU admission, % (n)

44.4% (24)

1.8% (2)

 Length of ICU stay, median (IQR)

3.5 (1–8)

1.5 (1–2)

 Required invasive ventilation, % (n)

9.2% (5)

–

 Length of hospital stay, days, median (IQR)

13 (9–15)

5 (5–6)

 WBC, median (IQR) x 10⁹/L

10.92 (7.52–19.54)

13.6 (8.07–17.92)

 PLT, median (IQR) x 10¹²/L

219.00 (127.25–326.50)

279.00 (236.50–366.75)

 CRP, median (IQR), mg/L

162.00 (82.65–262.75)

42.90 (13.21–102.15)

 PCT, median (IQR), ng/mL

3.95 (0.69–12.94)

0.34 (0.11–2.28)

 Positive blood culture, % (n)

1.8% (1)

–

 Eotaxin, median (IQR), pg/mL

61.77 (46.18–112.62)

83.66 (57.69–121.40)

 G-CSF, median (IQR), pg/mL

219.11 (58.56–524.93)

212.88 (94.66–710.43)

 IFN gamma, median (IQR), pg/mL

10.72 (4.34–25.08)

15.06 (7.70–53.43)

 IL-10, median (IQR), pg/mL

23.03 (11.46–73.61)

37.17 (20.16–81.79)

 IL-1ra, median (IQR), pg/mL

38.70 (17.27–143.67)

42.883 (14.20–102.13)

 IL-6, median (IQR), pg/mL

48.95 (24.45–235.00)

22.55 (8.63–58.55)

 IL-8, median (IQR), pg/mL

16.54 (8.82–36.40)

14.14 (6.91–21.17)

 IP-10, median (IQR), pg/mL

786.33 (347.72–2202.61)

975.72 (552.25–2103.36)

 MCP-1, median (IQR), pg/mL

393.44 (274.28–703.09)

472.96 (302.29–841.54)

 PAI-1, median (IQR), pg/mL

101,564.90 (117.88–150,633.47)

83,516.50 (143.80–163,213.34)

 sFAS, median (IQR), pg/mL

3171.12 (2592.33–4280.32)

2738.20 (2154.14–3552.89)

 sVACM-1, median (IQR), pg/mL

505,020.07 (1262.56–806,747.45)

352,718.78 (1081.54–1,034,808.95)